Dechra Pharmaceuticals (LSE:DPH) Debt-to-Equity : 0.67 (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Debt-to-Equity?

Dechra Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £3.9 Mil. Dechra Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £500.6 Mil. Dechra Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £755.2 Mil. Dechra Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2023 was 0.67.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Dechra Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

LSE:DPH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16 Med: 0.56 Max: 0.67
Current: 0.67

During the past 13 years, the highest Debt-to-Equity Ratio of Dechra Pharmaceuticals was 0.67. The lowest was 0.16. And the median was 0.56.

LSE:DPH's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.28 vs LSE:DPH: 0.67

Dechra Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Dechra Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Debt-to-Equity Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.61

0.56

0.50

0.49

0.67

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															0.50	0.50	0.49	0.61	0.67

Competitive Comparison of Dechra Pharmaceuticals's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Dechra Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dechra Pharmaceuticals's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dechra Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Dechra Pharmaceuticals's Debt-to-Equity falls into.

Dechra Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Dechra Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.9	+	500.6)	/	755.2
	=	0.67

Dechra Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.9	+	500.6)	/	755.2
	=	0.67

Dechra Pharmaceuticals (LSE:DPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Dechra Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Dechra Pharmaceuticals (LSE:DPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines